AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes

Recruitingn/aAges any - anyAllSecond Xiangya Hospital of Central South Universi…
💬

In plain words

What the trial is, and whether it could suit you

The aim of the China Diabetes Type 1 Study (CD1S) is to conduct a nationwide type 1 diabetes (T1D) registry study in patients with T1D and in pediatric adolescent patients with diabetes who had an age of onset \<= 20 years. CD1S compromises a retrospective study enrolling inpatients hospitalized from Jan 1st, 2016 to Dec 31, 2021, and a prospective study beginning from the year 2022.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * 1\. Patients with type 1 diabetes mellitus of any duration; meeting criteria (1) or any of (2) or any of (3) 1. Clinical diagnosis of type 1 diabetes by a specialist 2. Age at onset \< 15 years; no overweight or obesity at onset; previous diabetic ketoacidosis; highest random C-peptide \< 200 pmol/L 3. Initiation and continuation of insulin therapy (except pancreatic or islet transplantation) after diagnosis; positive islet autoantibodies Or 2. Children and adolescents with diabetes mellitus at age of onset \<= 20 years, regardless of type and duration of disease. Exclusion Criteria: * For enrolment of patients with T1D, exclusion was made if any of the following criteria were met (not applicable to those with onset under 20 years of age) * No insulin dependence for at least 6 months after diagnosis of diabetes mellitus. * No DKA for 1 month off insulin for those with a history of diabetes \> 1 year. ③ C-peptide \> 800 pmol/L at any time point.
💊

What it tests

  • Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
📍

Where

11 sites
Gansu Provincial People's Hospital
Lanzhou, China
Shenzhen Second People's Hospital
Shenzhen, China
Hainan General Hospital
Haikou, China
the First Affiliated Hospital of Harbin Medical University
Harbin, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China
The Second Xiangya Hospital, Central South University
Changsha, China
The First Affiliated Hospital of Nanjing Medical University
Nanjing, China
Heji Hospital Affiliated to Changzhi Medical College
Changzhi, China

…and 3 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy